ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet13124ometendo-13124Research ArticleОБЗОРЫREVIEWSМинеральные нарушения у пациентов с хроническими заболеваниями печени. Часть 1: эпидемиология и патофизиологияMineral disorders in patients with chronic liver disease. Part 1: epidemiology and pathophysiologyhttps://orcid.org/0000-0003-2669-9457ГорбачеваА. М.GorbachevaA. M.

Горбачева Анна Максимовна, к.м.н.

115478, Москва, ул. Дм. Ульянова, д. 11

ResearcherID: HKO-2637-2023

 

Scopus Author ID: 57190977461

Anna M. Gorbacheva, MD, PhD

11 Dm.Ulyanova street, 115478, Moscow

ResearcherID: HKO-2637-2023

 

Scopus Author ID: 57190977461

ann.gorbachewa@yandex.ruhttps://orcid.org/0000-0001-5952-5846БибикЕ. Е.BibikE. E.

Бибик Екатерина Евгеньевна, к.м.н.

115478, Москва, ул. Дм. Ульянова, д. 11

ResearcherID: AAY-3052-2020

 

Scopus Author ID: 57195679482

Ekaterina E. Bibik, MD, PhD

11 Dm.Ulyanova street, 115478, Moscow

ResearcherID: AAY-3052-2020

 

Scopus Author ID: 57195679482

bibik.ekaterina@endocrincentr.ruhttps://orcid.org/0000-0002-7285-6874ЛавренюкА. А.LavreniukA. A.

Лавренюк Анастасия Андреевна

115478, Москва, ул. Дм. Ульянова, д. 11

ResearcherID: ABF-4392-2022

 

Scopus Author ID: 7101843976

Anastasia A. Lavreniuk, MD

11 Dm.Ulyanova street, 115478, Moscow

ResearcherID: ABF-4392-2022

 

Scopus Author ID: 7101843976

lavrenyuk.anastasiya@endocrincentr.ruhttps://orcid.org/0000-0001-6667-062XЕремкинаА. К.EremkinaA. K.

Еремкина Анна Константиновна, к.м.н.

115478, Москва, ул. Дм. Ульянова, д. 11

ResearcherID: R-8848-2019

 

Scopus Author ID: 57197775339

Anna K. Eremkina, MD, PhD

11 Dm.Ulyanova street, 115478, Moscow

ResearcherID: R-8848-2019

 

Scopus Author ID: 57197775339

eremkina.anna@endocrincentr.ruhttps://orcid.org/0000-0002-0532-9126ТихоновИ. Н.TikhonovI. N.

Тихонов Игорь Николаевич

Scopus Author ID: 57200597669

Igor N. Tikhonov, MD

ResearcherID: ABC-4408-2020

 

Scopus Author ID: 57200597669

antihbs@gmail.comhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна, д.м.н., профессор

115478, Москва, ул. Дм. Ульянова, д. 11 

ResearcherID: AAY-3761-2020

 

Scopus Author ID: 35269746000

Natalia G. Mokrysheva, MD, PhD, Professor

11 Dm.Ulyanova street, 115478, Moscow

ResearcherID: AAY-3761-2020

 

Scopus Author ID: 35269746000

mokrisheva.natalia@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CenterRussian FederationИКМ им. Н.В. Склифосовского Первого МГМУ имени И.М.СеченоваРоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation202406092024214373381Copyright © Горбачева А.М., Бибик Е.Е., Лавренюк А.А., Еремкина А.К., Тихонов И.Н., Мокрышева Н.Г., 20252025Горбачева А.М., Бибик Е.Е., Лавренюк А.А., Еремкина А.К., Тихонов И.Н., Мокрышева Н.Г.Gorbacheva A.M., Bibik E.E., Lavreniuk A.A., Eremkina A.K., Tikhonov I.N., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13124

Хронические заболевания печени относятся к значимым проблемам здравоохранения во всем мире, а их последствия обуславливают развитие различных минеральных нарушений, которые встречаются у 75% пациентов. Среди минеральных нарушений, развивающихся при хронических заболеваниях печени, наибольшее клиническое значение имеет остеопороз (до 30% больных). Переломы случаются, по разным данным, у 7–35% пациентов. Существует представление о целом ряде механизмов, влияющих на состояние минерального обмена при хронических заболеваниях печени: от нарушения метаболизма витамина D до синтеза провоспалительных цитокинов и функции кишечной микробиоты. На сегодняшний день эти процессы остаются недостаточно изученными: так, не до конца ясны аспекты, касающиеся функционирования околощитовидных желез при хронических заболеваниях печени; нет четкого представления о преобладающих процессах в костной ткани (анти- или прорезорбтивных). Это обусловливает несовершенство профилактических и терапевтических подходов при минеральных нарушениях вследствие хронических заболеваний печени и необходимости дальнейших исследований в этом направлении. Первая часть настоящего обзора посвящена вопросам эпидемиологии и патофизиологии нарушений минерального обмена при данных состояниях; вторая часть обзора будет касаться современных терапевтических подходов

Chronic liver disease is a significant public health problem worldwide, and its consequences lead to the development of various mineral disorders, which occur in 75% of patients. Osteoporosis (up to 30% of patients) has the greatest clinical significance among the mineral disorders that develop in chronic liver disease. Fractures occur, according to different data, in 7-35% of patients. There are number of mechanisms influencing the state of mineral metabolism in chronic liver diseases: from the disturbance of vitamin D metabolism to the synthesis of pro-inflammatory cytokines and the function of intestinal microbiota. To date, these processes remain insufficiently studied: for example, aspects concerning the functioning of parathyroid glands in chronic liver diseases are not completely clear; there is no clear idea about the predominant processes in bone tissue (anti- or proresorptive). This determines the imperfection of prophylactic and therapeutic approaches in mineral disorders due to chronic liver diseases and the need for further research in this direction. The first part of this review focuses on the epidemiology and pathophysiology of mineral metabolism disorders in these conditions; the second part of the review will focus on current therapeutic approaches

Цирроз печениостеопорозвитамин Dliver cirrhosisosteoporosisvitamin DРабота проведена в рамках гранта РНФ №24-25-00348 «Нарушения метаболизма витамина D и особенности костного ремоделирования у пациентов с циррозом печени различной этиологии»ReferencesCheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken). 2021;17(5):365-370. doi: https://doi.org/10.1002/cld.1061Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken). 2021;17(5):365-370. doi: https://doi.org/10.1002/cld.1061Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3). doi: https://doi.org/10.1016/S2468-1253(19)30349-8Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3). doi: https://doi.org/10.1016/S2468-1253(19)30349-8Giouleme O, Vyzantiadis T, Nikolaidis N, et al. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006;53(72):938-943Giouleme O, Vyzantiadis T, Nikolaidis N, et al. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006;53(72):938-943Zheng JP, Miao HX, Zheng SW, et al. Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. Medicine (United States). 2018;97(20). doi: https://doi.org/10.1097/MD.0000000000010645Zheng JP, Miao HX, Zheng SW, et al. Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. Medicine (United States). 2018;97(20). doi: https://doi.org/10.1097/MD.0000000000010645Patel N, Muñoz SJ. Bone disease in cirrhosis. Clin Liver Dis (Hoboken). 2015;6(4). doi: https://doi.org/10.1002/cld.498Patel N, Muñoz SJ. Bone disease in cirrhosis. Clin Liver Dis (Hoboken). 2015;6(4). doi: https://doi.org/10.1002/cld.498Nakchbandi IA. Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications. World J Gastroenterol. 2014;20(28). doi: https://doi.org/10.3748/wjg.v20.i28.9427Nakchbandi IA. Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications. World J Gastroenterol. 2014;20(28). doi: https://doi.org/10.3748/wjg.v20.i28.9427Compston JE, McClung MR, Leslie WD. Osteoporosis. The Lancet. 2019;393(10169):364-376. doi: https://doi.org/10.1016/S0140-6736(18)32112-3Compston JE, McClung MR, Leslie WD. Osteoporosis. The Lancet. 2019;393(10169):364-376. doi: https://doi.org/10.1016/S0140-6736(18)32112-3Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1). doi: https://doi.org/10.1016/j.jhep.2018.06.024Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1). doi: https://doi.org/10.1016/j.jhep.2018.06.024Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet. 2001;357(9253). doi: https://doi.org/10.1016/S0140-6736(00)03641-2Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet. 2001;357(9253). doi: https://doi.org/10.1016/S0140-6736(00)03641-2Navasa M, Monegal A, Guañabens N, et al. Bone fractures in liver transplant patients. Rheumatology. 1994;33(1). doi: https://doi.org/10.1093/rheumatology/33.1.52Navasa M, Monegal A, Guañabens N, et al. Bone fractures in liver transplant patients. Rheumatology. 1994;33(1). doi: https://doi.org/10.1093/rheumatology/33.1.52Топчеева О.Н., Дроздов В.Н., Эмбутниекс Ю.В., Вяжевич Ю.В. Минеральная плотность костной ткани у больных циррозом печени // Терапевтическая гастроэнетрология. — 2009. — №8. — С. 51-55.Topcheeva ON, Drozdov VN, Embutnieks YV, Vyazhevich YV. Mineral’naya plotnost’ kostnoj tkani u bol’nyh cirrozom pecheni // Terapevticheskaya gastroenetrologiya. 2009;8:51-55 (In Russ.)Топчеева О.Н. Особенности нарушения минеральной плотности костной ткани у больных циррозом печени различной этиологии: Дисс. … мед. наук. — М., 2010. – 115с.Topcheeva ON. Osobennosti narusheniya mineral’noj plotnosti kostnoj tkani u bol’nyh cirrozom pecheni razlichnoj etiologii: Diss. … med. nauk. M. 2010:115 (In Russ.)Киргуева О.И. Состояние костной ткани у мужчин, страдающих циррозом печени: Дисс. … мед. наук. — Волгоград, 2017. — 124 с.Kirgueva OI. Sostoyanie kostnoj tkani u muzhchin, stradayushchih cirrozom pecheni: Diss. … med. nauk. Volgograd. 2017:124 (In Russ.)Ehnert S, Aspera-Werz RH, Ruoß M, et al. Hepatic Osteodystrophy- Molecular Mechanisms Proposed to Favor Its Development. Int J Mol Sci. 2019;20(10). doi: https://doi.org/10.3390/ijms20102555Ehnert S, Aspera-Werz RH, Ruoß M, et al. Hepatic Osteodystrophy- Molecular Mechanisms Proposed to Favor Its Development. Int J Mol Sci. 2019;20(10). doi: https://doi.org/10.3390/ijms20102555Wintermeyer E, Ihle C, Ehnert S, et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8(6). doi: https://doi.org/10.3390/nu8060319Wintermeyer E, Ihle C, Ehnert S, et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8(6). doi: https://doi.org/10.3390/nu8060319Holick MF. Vitamin D: A D-lightful solution for health. In: Journal of Investigative Medicine. 2011;59. doi: https://doi.org/10.2310/JIM.0b013e318214ea2dHolick MF. Vitamin D: A D-lightful solution for health. In: Journal of Investigative Medicine. 2011;59. doi: https://doi.org/10.2310/JIM.0b013e318214ea2dNussler AK, Wildemann B, Freude T, et al. Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: A mouse model to analyse the liver-bone axis. Arch Toxicol. 2014;88(4). doi: https://doi.org/10.1007/s00204-013-1191-5Nussler AK, Wildemann B, Freude T, et al. Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: A mouse model to analyse the liver-bone axis. Arch Toxicol. 2014;88(4). doi: https://doi.org/10.1007/s00204-013-1191-5Hochrath K, Ehnert S, Ackert-Bicknell CL, et al. Modeling hepatic osteodystrophy in Abcb4 deficient mice. Bone. 2013;55(2). doi: https://doi.org/10.1016/j.bone.2013.03.012Hochrath K, Ehnert S, Ackert-Bicknell CL, et al. Modeling hepatic osteodystrophy in Abcb4 deficient mice. Bone. 2013;55(2). doi: https://doi.org/10.1016/j.bone.2013.03.012Chongthavornvasana S, Lertudomphonwanit C, Mahachoklertwattana P, Korwutthikulrangsri M. Determination of Optimal Vitamin D Dosage in Children with Cholestasis. BMC Pediatr. 2023;23(1). doi: https://doi.org/10.1186/s12887-023-04113-yChongthavornvasana S, Lertudomphonwanit C, Mahachoklertwattana P, Korwutthikulrangsri M. Determination of Optimal Vitamin D Dosage in Children with Cholestasis. BMC Pediatr. 2023;23(1). doi: https://doi.org/10.1186/s12887-023-04113-yAbdel-Rahman N, Sharawy MH, Megahed N, El-Awady MS. Vitamin D3 abates BDL-induced cholestasis and fibrosis in rats via regulating Hedgehog pathway. Toxicol Appl Pharmacol. 2019;380. doi: https://doi.org/10.1016/j.taap.2019.114697Abdel-Rahman N, Sharawy MH, Megahed N, El-Awady MS. Vitamin D3 abates BDL-induced cholestasis and fibrosis in rats via regulating Hedgehog pathway. Toxicol Appl Pharmacol. 2019;380. doi: https://doi.org/10.1016/j.taap.2019.114697Zhao XY, Li J, Wang JH, et al. Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients. Medicine (United States). 2016;95(27). doi: https://doi.org/10.1097/MD.0000000000003926Zhao XY, Li J, Wang JH, et al. Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients. Medicine (United States). 2016;95(27). doi: https://doi.org/10.1097/MD.0000000000003926Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55(9). doi: https://doi.org/10.1007/s10620-009-1069-9Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55(9). doi: https://doi.org/10.1007/s10620-009-1069-9DeLuca HF. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014;3. doi: https://doi.org/10.1038/bonekey.2013.213DeLuca HF. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014;3. doi: https://doi.org/10.1038/bonekey.2013.213Shinchuk L, Holick MF. Vitamin D and rehabilitation: Improving functional outcomes. Nutrition in Clinical Practice. 2007;22(3). doi: https://doi.org/10.1177/0115426507022003297Shinchuk L, Holick MF. Vitamin D and rehabilitation: Improving functional outcomes. Nutrition in Clinical Practice. 2007;22(3). doi: https://doi.org/10.1177/0115426507022003297Booth DR, Ding N, Parnell GP, et al. Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitudedependent autoimmune diseases. Genes Immun. 2016;17(4):213-219. doi: https://doi.org/10.1038/gene.2016.12Booth DR, Ding N, Parnell GP, et al. Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitudedependent autoimmune diseases. Genes Immun. 2016;17(4):213-219. doi: https://doi.org/10.1038/gene.2016.12Christensen MHE, Apalset EM, Nordbø Y, Varhaug JE, Mellgren G, Lien EA. 1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism. PLoS One. 2013;8(2). doi: https://doi.org/10.1371/journal.pone.0056019Christensen MHE, Apalset EM, Nordbø Y, Varhaug JE, Mellgren G, Lien EA. 1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism. PLoS One. 2013;8(2). doi: https://doi.org/10.1371/journal.pone.0056019Christakos S, Dhawan P, Porta A, Mady LJ, Seth T. Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol. 2011;347(1-2). doi: https://doi.org/10.1016/j.mce.2011.05.038Christakos S, Dhawan P, Porta A, Mady LJ, Seth T. Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol. 2011;347(1-2). doi: https://doi.org/10.1016/j.mce.2011.05.038Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis and aging. Bone Res. 2016;4. doi: https://doi.org/10.1038/boneres.2016.41Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis and aging. Bone Res. 2016;4. doi: https://doi.org/10.1038/boneres.2016.41Shymanskyi I, Lisakovska O, Mazanova A, Labudzynskyi D, Veliky M. Vitamin D3 modulates impaired crosstalk between RANK and glucocorticoid receptor signaling in bone marrow cells after chronic prednisolone administration. Front Endocrinol (Lausanne). 2018;9(JUN). doi: https://doi.org/10.3389/fendo.2018.00303Shymanskyi I, Lisakovska O, Mazanova A, Labudzynskyi D, Veliky M. Vitamin D3 modulates impaired crosstalk between RANK and glucocorticoid receptor signaling in bone marrow cells after chronic prednisolone administration. Front Endocrinol (Lausanne). 2018;9(JUN). doi: https://doi.org/10.3389/fendo.2018.00303Wacker M, Holiack MF. Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1). doi: https://doi.org/10.3390/nu5010111Wacker M, Holiack MF. Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1). doi: https://doi.org/10.3390/nu5010111Takahashi N, Udagawa N, Suda T. Vitamin D endocrine system and osteoclasts. Bonekey Rep. 2014;3. doi: https://doi.org/10.1038/bonekey.2014.17Takahashi N, Udagawa N, Suda T. Vitamin D endocrine system and osteoclasts. Bonekey Rep. 2014;3. doi: https://doi.org/10.1038/bonekey.2014.17Prié D, Forand A, Francoz C, et al. Plasma Fibroblast Growth Factor 23 Concentration Is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List. PLoS One. 2013;8(6). doi: https://doi.org/10.1371/journal.pone.0066182Prié D, Forand A, Francoz C, et al. Plasma Fibroblast Growth Factor 23 Concentration Is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List. PLoS One. 2013;8(6). doi: https://doi.org/10.1371/journal.pone.0066182He X, Shen Y, Ma X, et al. The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018;45(7). doi: https://doi.org/10.1111/1440-1681.12933He X, Shen Y, Ma X, et al. The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018;45(7). doi: https://doi.org/10.1111/1440-1681.12933Bihari C, Lal D, Thakur M, et al. Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy. Hepatol Commun. 2018;2(9). doi: https://doi.org/10.1002/hep4.1234Bihari C, Lal D, Thakur M, et al. Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy. Hepatol Commun. 2018;2(9). doi: https://doi.org/10.1002/hep4.1234Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh- Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4). doi: https://doi.org/10.1152/ajprenal.00360.2010Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh- Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4). doi: https://doi.org/10.1152/ajprenal.00360.2010Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatric Nephrology. 2010;25(11). doi: https://doi.org/10.1007/s00467-010-1565-3Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatric Nephrology. 2010;25(11). doi: https://doi.org/10.1007/s00467-010-1565-3Fisher L, Fisher A. Vitamin D and Parathyroid Hormone in Outpatients With Noncholestatic Chronic Liver Disease. Clinical Gastroenterology and Hepatology. 2007;5(4). doi: https://doi.org/10.1016/j.cgh.2006.10.015Fisher L, Fisher A. Vitamin D and Parathyroid Hormone in Outpatients With Noncholestatic Chronic Liver Disease. Clinical Gastroenterology and Hepatology. 2007;5(4). doi: https://doi.org/10.1016/j.cgh.2006.10.015Islam MZ, Viljakainen HT, Kärkkäinen MUM, Saarnio E, Laitinen K, Lamberg-Allardt C. Prevalence of vitamin D deficiency and secondary hyperparathyroidism during winter in pre-menopausal Bangladeshi and Somali immigrant and ethnic Finnish women: associations with forearm bone mineral density. Br J Nutr. 2012;107(2):277-283. doi: https://doi.org/10.1017/S0007114511002893Islam MZ, Viljakainen HT, Kärkkäinen MUM, Saarnio E, Laitinen K, Lamberg-Allardt C. Prevalence of vitamin D deficiency and secondary hyperparathyroidism during winter in pre-menopausal Bangladeshi and Somali immigrant and ethnic Finnish women: associations with forearm bone mineral density. Br J Nutr. 2012;107(2):277-283. doi: https://doi.org/10.1017/S0007114511002893Narayanasamy K, Karthick R, Raj AK. High Prevalent Hypovitaminosis D Is Associated with Dysregulation of Calcium-parathyroid Hormone-vitamin D Axis in Patients with Chronic Liver Diseases. J Clin Transl Hepatol. 2019;7(1):15-20. doi: https://doi.org/10.14218/JCTH.2018.00018Narayanasamy K, Karthick R, Raj AK. High Prevalent Hypovitaminosis D Is Associated with Dysregulation of Calcium-parathyroid Hormone-vitamin D Axis in Patients with Chronic Liver Diseases. J Clin Transl Hepatol. 2019;7(1):15-20. doi: https://doi.org/10.14218/JCTH.2018.00018Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol. 2001;16(9):1022-1027. doi: https://doi.org/10.1046/j.1440-1746.2001.02561.xDuarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol. 2001;16(9):1022-1027. doi: https://doi.org/10.1046/j.1440-1746.2001.02561.xMarek B, Kajdaniuk D, Niedziołka D, et al. Growth hormone/insulinlike growth factor-1 axis, calciotropic hormones and bone mineral density in young patients with chronic viral hepatitis. Endokrynol Pol. 2015;66(1):22-29. doi: https://doi.org/10.5603/EP.2015.0005Marek B, Kajdaniuk D, Niedziołka D, et al. Growth hormone/insulinlike growth factor-1 axis, calciotropic hormones and bone mineral density in young patients with chronic viral hepatitis. Endokrynol Pol. 2015;66(1):22-29. doi: https://doi.org/10.5603/EP.2015.0005Corey RL, Whitaker MD, Crowell MD, et al. Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transplant. 2014;28(5). doi: https://doi.org/10.1111/ctr.12351Corey RL, Whitaker MD, Crowell MD, et al. Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transplant. 2014;28(5). doi: https://doi.org/10.1111/ctr.12351Dibble JB, Sheridan P, Hampshire R, Hardy GJ, Losowsky MS. Evidence for secondary hyperparathyroidism in the osteomalacia associated with chronic liver disease. Clin Endocrinol (Oxf ). 1981;15(4):373-383. doi: https://doi.org/10.1111/j.1365-2265.1981.tb00677.xDibble JB, Sheridan P, Hampshire R, Hardy GJ, Losowsky MS. Evidence for secondary hyperparathyroidism in the osteomalacia associated with chronic liver disease. Clin Endocrinol (Oxf ). 1981;15(4):373-383. doi: https://doi.org/10.1111/j.1365-2265.1981.tb00677.xGerhardt A, Greenberg A, Reilly JJ, Van Thiel DH. Hypercalcemia. A complication of advanced chronic liver disease. Arch Intern Med. 1987;147(2):274-277. doi: https://doi.org/10.1001/archinte.147.2.274Gerhardt A, Greenberg A, Reilly JJ, Van Thiel DH. Hypercalcemia. A complication of advanced chronic liver disease. Arch Intern Med. 1987;147(2):274-277. doi: https://doi.org/10.1001/archinte.147.2.274Compston JE, Greer S, Skingle SJ, et al. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol. 1996;25(5):715-718. doi: https://doi.org/10.1016/s0168-8278(96)80243-1Compston JE, Greer S, Skingle SJ, et al. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol. 1996;25(5):715-718. doi: https://doi.org/10.1016/s0168-8278(96)80243-1Prytuła A, Walle J Vande, Van Vlierberghe H, et al. Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study. Endocrine. 2016;52(1):93-102. doi: https://doi.org/10.1007/s12020-015-0757-9Prytuła A, Walle J Vande, Van Vlierberghe H, et al. Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study. Endocrine. 2016;52(1):93-102. doi: https://doi.org/10.1007/s12020-015-0757-9Klein GL, Soriano H, Shulman RJ, Levy M, Jones G, Langman CB. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant. 2002;6(2):136-140. doi: https://doi.org/10.1034/j.1399-3046.2002.01060.xKlein GL, Soriano H, Shulman RJ, Levy M, Jones G, Langman CB. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant. 2002;6(2):136-140. doi: https://doi.org/10.1034/j.1399-3046.2002.01060.xMarie PJ, Kassem M. Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165(1). doi: https://doi.org/10.1530/EJE-11-0132Marie PJ, Kassem M. Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165(1). doi: https://doi.org/10.1530/EJE-11-0132Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. Hepatology. 2011;54(6). doi: https://doi.org/10.1002/hep.24605Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. Hepatology. 2011;54(6). doi: https://doi.org/10.1002/hep.24605Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14(1). doi: https://doi.org/10.1007/s11739-018-1874-2Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14(1). doi: https://doi.org/10.1007/s11739-018-1874-2Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96. doi: https://doi.org/10.1016/j.bone.2016.10.007Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96. doi: https://doi.org/10.1016/j.bone.2016.10.007Rhee Y, Kim WJ, Han KJ, Lim SK, Kim SH. Effect of liver dysfunction on circulating sclerostin. J Bone Miner Metab. 2014;32(5). doi: https://doi.org/10.1007/s00774-013-0524-zRhee Y, Kim WJ, Han KJ, Lim SK, Kim SH. Effect of liver dysfunction on circulating sclerostin. J Bone Miner Metab. 2014;32(5). doi: https://doi.org/10.1007/s00774-013-0524-zReid IR. Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab. BioDrugs. 2017;31(4). doi: https://doi.org/10.1007/s40259-017-0229-2Reid IR. Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab. BioDrugs. 2017;31(4). doi: https://doi.org/10.1007/s40259-017-0229-2Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver International. 2018;38(5). doi: https://doi.org/10.1111/liv.13730Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver International. 2018;38(5). doi: https://doi.org/10.1111/liv.13730Kimura K, Terasaka T, Iwata N, et al. Combined effects of androgen and growth hormone on osteoblast marker expression in mouse C2C12 and MC3T3-E1 cells induced by bone morphogenetic protein. J Clin Med. 2017;6(1). doi: https://doi.org/10.3390/jcm6010006Kimura K, Terasaka T, Iwata N, et al. Combined effects of androgen and growth hormone on osteoblast marker expression in mouse C2C12 and MC3T3-E1 cells induced by bone morphogenetic protein. J Clin Med. 2017;6(1). doi: https://doi.org/10.3390/jcm6010006Qiu T, Crane JL, Xie L, Xian L, Xie H, Cao X. IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition. Bone Res. 2018;6(1). doi: https://doi.org/10.1038/s41413-017-0002-7Qiu T, Crane JL, Xie L, Xian L, Xie H, Cao X. IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition. Bone Res. 2018;6(1). doi: https://doi.org/10.1038/s41413-017-0002-7Guerra-Menéndez L, Sádaba MC, Puche JE, et al. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med. 2013;11(1). doi: https://doi.org/10.1186/1479-5876-11-271Guerra-Menéndez L, Sádaba MC, Puche JE, et al. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med. 2013;11(1). doi: https://doi.org/10.1186/1479-5876-11-271Krishnan V. Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation. 2006;116(5):1202-1209. doi: https://doi.org/10.1172/JCI28551Krishnan V. Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation. 2006;116(5):1202-1209. doi: https://doi.org/10.1172/JCI28551Nasu M, Sugimoto T, Chihara M, Hiraumi M, Kurimoto F, Chihara K. Effect of natural menopause on serum levels of IGF-I and IGFbinding proteins: Relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol. 1997;136(6). doi: https://doi.org/10.1530/eje.0.1360608Nasu M, Sugimoto T, Chihara M, Hiraumi M, Kurimoto F, Chihara K. Effect of natural menopause on serum levels of IGF-I and IGFbinding proteins: Relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol. 1997;136(6). doi: https://doi.org/10.1530/eje.0.1360608de la Garza RG, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I. Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res. 2017;9(4). doi: https://doi.org/10.14740/jocmr2761wde la Garza RG, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I. Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res. 2017;9(4). doi: https://doi.org/10.14740/jocmr2761wCemborain A, Castilla-Cortázar I, García M, et al. Osteopenia in rats with liver cirrhosis: Beneficial effects of IGF-I treatment. J Hepatol. 1998;28(1). doi: https://doi.org/10.1016/S0168-8278(98)80211-0Cemborain A, Castilla-Cortázar I, García M, et al. Osteopenia in rats with liver cirrhosis: Beneficial effects of IGF-I treatment. J Hepatol. 1998;28(1). doi: https://doi.org/10.1016/S0168-8278(98)80211-0Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci. 2018;19(5). doi: https://doi.org/10.3390/ijms19051308Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci. 2018;19(5). doi: https://doi.org/10.3390/ijms19051308Golds G, Houdek D, Arnason T. Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. Int J Endocrinol. 2017;2017. doi: https://doi.org/10.1155/2017/4602129Golds G, Houdek D, Arnason T. Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. Int J Endocrinol. 2017;2017. doi: https://doi.org/10.1155/2017/4602129Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am. 2003;32(1). doi: https://doi.org/10.1016/S0889-8529(02)00078-6Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am. 2003;32(1). doi: https://doi.org/10.1016/S0889-8529(02)00078-6Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev. 2018;39. doi: https://doi.org/10.1016/j.cytogfr.2018.01.002Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev. 2018;39. doi: https://doi.org/10.1016/j.cytogfr.2018.01.002Wu Q, Zhou X, Huang D, Ji Y, Kang F. IL-6 enhances osteocytemediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cellular Physiology and Biochemistry. 2017;41(4). doi: https://doi.org/10.1159/000465455Wu Q, Zhou X, Huang D, Ji Y, Kang F. IL-6 enhances osteocytemediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cellular Physiology and Biochemistry. 2017;41(4). doi: https://doi.org/10.1159/000465455Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2002;87(11). doi: https://doi.org/10.1210/jc.2001-011814Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2002;87(11). doi: https://doi.org/10.1210/jc.2001-011814Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. Advances in Clinical and Experimental Medicine. 2018;27(1). doi: https://doi.org/10.17219/acem/67561Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. Advances in Clinical and Experimental Medicine. 2018;27(1). doi: https://doi.org/10.17219/acem/67561Norris CA, He M, Kang LI, et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS One. 2014;9(4). doi: https://doi.org/10.1371/journal.pone.0096053Norris CA, He M, Kang LI, et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS One. 2014;9(4). doi: https://doi.org/10.1371/journal.pone.0096053Shimada M, Matsumata T, Taketomi A, et al. The role of interleukin-6, interleukin-16, tumor necrosis factor-alpha and endotoxin in hepatic resection. Hepatogastroenterology. 1995;42(5):691-697Shimada M, Matsumata T, Taketomi A, et al. The role of interleukin-6, interleukin-16, tumor necrosis factor-alpha and endotoxin in hepatic resection. Hepatogastroenterology. 1995;42(5):691-697Hernandez-Barragan A, Montes-de-Oca-Angeles D, Lemus- Peña M, et al. Serum determination of IL-1β and IL-1RA in patients with chronic liver diseases. Ann Hepatol. 2022;27. doi: https://doi.org/10.1016/j.aohep.2022.100864Hernandez-Barragan A, Montes-de-Oca-Angeles D, Lemus- Peña M, et al. Serum determination of IL-1β and IL-1RA in patients with chronic liver diseases. Ann Hepatol. 2022;27. doi: https://doi.org/10.1016/j.aohep.2022.100864Ruscitti P, Cipriani P, Carubbi F, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm. 2015;2015. doi: https://doi.org/10.1155/2015/782382Ruscitti P, Cipriani P, Carubbi F, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm. 2015;2015. doi: https://doi.org/10.1155/2015/782382Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1). doi: https://doi.org/10.1111/imr.12621Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1). doi: https://doi.org/10.1111/imr.12621Nakamura I, Jimi E. Regulation of Osteoclast Differentiation and Function by Interleukin-1. Vitam Horm. 2006;74. doi: https://doi.org/10.1016/S0083-6729(06)74015-8Nakamura I, Jimi E. Regulation of Osteoclast Differentiation and Function by Interleukin-1. Vitam Horm. 2006;74. doi: https://doi.org/10.1016/S0083-6729(06)74015-8Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: Interactions of the bone and immune system. Endocr Rev. 2008;29(4). doi: https://doi.org/10.1210/er.2007-0038Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: Interactions of the bone and immune system. Endocr Rev. 2008;29(4). doi: https://doi.org/10.1210/er.2007-0038Zhao S, Jiang J, Jing Y, et al. The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity. Cell Death Dis. 2020;11(1). doi: https://doi.org/10.1038/s41419-020-2264-zZhao S, Jiang J, Jing Y, et al. The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity. Cell Death Dis. 2020;11(1). doi: https://doi.org/10.1038/s41419-020-2264-zZhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. Journal of Experimental Medicine. 2012;209(2). doi: https://doi.org/10.1084/jem.20111566Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. Journal of Experimental Medicine. 2012;209(2). doi: https://doi.org/10.1084/jem.20111566Boyce BF, Li P, Yao Z, et al. TNFα and pathologic bone resorption. Keio Journal of Medicine. 2005;54(3). doi: https://doi.org/10.2302/kjm.54.127Boyce BF, Li P, Yao Z, et al. TNFα and pathologic bone resorption. Keio Journal of Medicine. 2005;54(3). doi: https://doi.org/10.2302/kjm.54.127Stojic J, Kukla M, Grgurevic I. The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status. Diagnostics. 2023;13(18). doi: https://doi.org/10.3390/diagnostics13182960Stojic J, Kukla M, Grgurevic I. The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status. Diagnostics. 2023;13(18). doi: https://doi.org/10.3390/diagnostics13182960Liu J, Yang D, Wang X, et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022;12. doi: https://doi.org/10.3389/fcimb.2022.774335Liu J, Yang D, Wang X, et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022;12. doi: https://doi.org/10.3389/fcimb.2022.774335Jeong H, Kim D. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20(17):4270. doi: https://doi.org/10.3390/ijms20174270Jeong H, Kim D. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20(17):4270. doi: https://doi.org/10.3390/ijms20174270Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: Osteoporosis, sarcopenia, and osteoporotic sarcopenia. Int J Mol Sci. 2021;22(5):1-33. doi: https://doi.org/10.3390/ijms22052604Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: Osteoporosis, sarcopenia, and osteoporotic sarcopenia. Int J Mol Sci. 2021;22(5):1-33. doi: https://doi.org/10.3390/ijms22052604Sumida K, Shrestha P, Mallisetty Y, et al. Incident Diuretic Use and Subsequent Risk of Bone Fractures: A Large Nationwide Observational Study of US Veterans. Mayo Clin Proc. 2024;99(6):913-926. doi: https://doi.org/10.1016/j.mayocp.2023.09.018Sumida K, Shrestha P, Mallisetty Y, et al. Incident Diuretic Use and Subsequent Risk of Bone Fractures: A Large Nationwide Observational Study of US Veterans. Mayo Clin Proc. 2024;99(6):913-926. doi: https://doi.org/10.1016/j.mayocp.2023.09.018van der Burgh AC, Oliai Araghi S, Zillikens MC, et al. The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study. Bone. 2020;138. doi: https://doi.org/10.1016/j.bone.2020.115475van der Burgh AC, Oliai Araghi S, Zillikens MC, et al. The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study. Bone. 2020;138. doi: https://doi.org/10.1016/j.bone.2020.115475

The authors declare that there are no conflicts of interest present.